FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023554430> ?p ?o ?g. }

• W2023554430 endingPage "579" @default.
• W2023554430 startingPage "571" @default.
• W2023554430 abstract "Some evidence suggests an increased risk of myocardial infarction and dysrhythmia events associated with beta(2)-agonist use in patients with chronic obstructive pulmonary disease (COPD). This prospective, multicenter, randomized, double-blind, placebo-controlled study compared the cardiac safety of formoterol and placebo in patients with COPD.After a 3-14-day run-in, 204 patients were randomized to receive formoterol 12 microg dry powder inhalation or matching placebo twice daily for 8 weeks. Twenty four-hour continuous electrocardiography (Holter monitoring) was performed at screening and after 2 and 8 weeks of treatment.Only a small number of patients met the predefined criteria for a proarrhythmic event (4 formoterol and 2 placebo patients). No patients had sustained postbaseline ventricular tachycardia events, postbaseline run of ventricular ectopic beats associated with relevant symptoms (e.g. hypotension, syncope), or an episode of ventricular flutter or fibrillation. Holter monitoring data were variable but showed no clinically meaningful differences between the formoterol and placebo groups, respectively, for variables such as (mean+/-SD at end of treatment): heart rate (80+/-8.6 vs. 80+/-10.6 bpm), number and rate of ventricular premature beats (total 732+/-2685.4 vs. 650+/-2090.6; rate 35+/-131.0 vs. 30+/-101.3 per h), ventricular tachycardia events (total 0.4+/-1.70 vs. 1.0+/-9.23; rate 0.02+/-0.082 vs. 0.05+/-0.479 per h), and supraventricular premature beats (total 504+/-1844.1 vs. 823+/-2961.8; rate 22+/-80.6 vs. 37+/-129.6 per h). Vital signs and electrocardiogram data, including corrected QT intervals (Bazett and Fridericia), were similar across treatment groups. The overall adverse event experience was similar in the formoterol (n=26 [27%]) and placebo (n=33 [31%]) groups. The most common adverse events, infections and respiratory events, were expected for this patient population. The incidence of cardiac adverse events was low (1 formoterol and 4 placebo patients).The results of this study confirm the good cardiovascular safety profile of formoterol in patients with COPD." @default.
• W2023554430 created "2016-06-24" @default.
• W2023554430 creator A5009003396 @default.
• W2023554430 creator A5021622181 @default.
• W2023554430 creator A5038647353 @default.
• W2023554430 creator A5048563562 @default.
• W2023554430 creator A5052421515 @default.
• W2023554430 creator A5061072757 @default.
• W2023554430 creator A5068808783 @default.
• W2023554430 date "2007-10-01" @default.
• W2023554430 modified "2023-10-14" @default.
• W2023554430 title "Cardiac safety of formoterol 12μg twice daily in patients with chronic obstructive pulmonary disease" @default.
• W2023554430 cites W1973517682 @default.
• W2023554430 cites W1989738601 @default.
• W2023554430 cites W1996275057 @default.
• W2023554430 cites W2006363187 @default.
• W2023554430 cites W2007527209 @default.
• W2023554430 cites W2023136584 @default.
• W2023554430 cites W2026998835 @default.
• W2023554430 cites W2030453913 @default.
• W2023554430 cites W2036324891 @default.
• W2023554430 cites W2065200453 @default.
• W2023554430 cites W2070687706 @default.
• W2023554430 cites W2071058793 @default.
• W2023554430 cites W2071412839 @default.
• W2023554430 cites W2072349084 @default.
• W2023554430 cites W2088785446 @default.
• W2023554430 cites W2106066604 @default.
• W2023554430 cites W2110783271 @default.
• W2023554430 cites W2111830238 @default.
• W2023554430 cites W2134122420 @default.
• W2023554430 cites W2143127068 @default.
• W2023554430 cites W2150613910 @default.
• W2023554430 cites W26491123 @default.
• W2023554430 cites W4247432378 @default.
• W2023554430 cites W4367331560 @default.
• W2023554430 doi "https://doi.org/10.1016/j.pupt.2006.06.003" @default.
• W2023554430 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16911869" @default.
• W2023554430 hasPublicationYear "2007" @default.
• W2023554430 type Work @default.
• W2023554430 sameAs 2023554430 @default.
• W2023554430 citedByCount "32" @default.
• W2023554430 countsByYear W20235544302012 @default.
• W2023554430 countsByYear W20235544302013 @default.
• W2023554430 countsByYear W20235544302014 @default.
• W2023554430 countsByYear W20235544302015 @default.
• W2023554430 countsByYear W20235544302016 @default.
• W2023554430 countsByYear W20235544302017 @default.
• W2023554430 countsByYear W20235544302018 @default.
• W2023554430 countsByYear W20235544302019 @default.
• W2023554430 countsByYear W20235544302022 @default.
• W2023554430 crossrefType "journal-article" @default.
• W2023554430 hasAuthorship W2023554430A5009003396 @default.
• W2023554430 hasAuthorship W2023554430A5021622181 @default.
• W2023554430 hasAuthorship W2023554430A5038647353 @default.
• W2023554430 hasAuthorship W2023554430A5048563562 @default.
• W2023554430 hasAuthorship W2023554430A5052421515 @default.
• W2023554430 hasAuthorship W2023554430A5061072757 @default.
• W2023554430 hasAuthorship W2023554430A5068808783 @default.
• W2023554430 hasConcept C126322002 @default.
• W2023554430 hasConcept C142724271 @default.
• W2023554430 hasConcept C164705383 @default.
• W2023554430 hasConcept C204787440 @default.
• W2023554430 hasConcept C27081682 @default.
• W2023554430 hasConcept C2776042228 @default.
• W2023554430 hasConcept C2776136866 @default.
• W2023554430 hasConcept C2776331378 @default.
• W2023554430 hasConcept C2776780178 @default.
• W2023554430 hasConcept C2777953023 @default.
• W2023554430 hasConcept C2779161974 @default.
• W2023554430 hasConcept C2779871671 @default.
• W2023554430 hasConcept C42219234 @default.
• W2023554430 hasConcept C500558357 @default.
• W2023554430 hasConcept C71924100 @default.
• W2023554430 hasConcept C84393581 @default.
• W2023554430 hasConceptScore W2023554430C126322002 @default.
• W2023554430 hasConceptScore W2023554430C142724271 @default.
• W2023554430 hasConceptScore W2023554430C164705383 @default.
• W2023554430 hasConceptScore W2023554430C204787440 @default.
• W2023554430 hasConceptScore W2023554430C27081682 @default.
• W2023554430 hasConceptScore W2023554430C2776042228 @default.
• W2023554430 hasConceptScore W2023554430C2776136866 @default.
• W2023554430 hasConceptScore W2023554430C2776331378 @default.
• W2023554430 hasConceptScore W2023554430C2776780178 @default.
• W2023554430 hasConceptScore W2023554430C2777953023 @default.
• W2023554430 hasConceptScore W2023554430C2779161974 @default.
• W2023554430 hasConceptScore W2023554430C2779871671 @default.
• W2023554430 hasConceptScore W2023554430C42219234 @default.
• W2023554430 hasConceptScore W2023554430C500558357 @default.
• W2023554430 hasConceptScore W2023554430C71924100 @default.
• W2023554430 hasConceptScore W2023554430C84393581 @default.
• W2023554430 hasIssue "5" @default.
• W2023554430 hasLocation W20235544301 @default.
• W2023554430 hasLocation W20235544302 @default.
• W2023554430 hasOpenAccess W2023554430 @default.
• W2023554430 hasPrimaryLocation W20235544301 @default.
• W2023554430 hasRelatedWork W1967841144 @default.
• W2023554430 hasRelatedWork W1987975497 @default.

• next